Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, its unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in its laboratories. Its medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.
Financial Statements
- Click here to download Regeneron Pharmaceuticals, Inc.'s Income Statement
- Click here to download Regeneron Pharmaceuticals, Inc.'s Balance Sheet
- Click here to download Regeneron Pharmaceuticals, Inc.'s Statement of Cash Flows
Key Info
- Industry: Pharmaceutical Preparation Manufacturing
- Sector: Manufacturing
- CEO Name: Leonard Schleifer
Key Statistics
- Stock Price: $605.18
- Dividend Yield: 0%
- Market Capitalization: $63,768,058,340
- Shares Outstanding: 105,106,409
- Number of Employees: 9,123
- Trailing 12-Month EPS: $55.32
- Trailing 12-Month DPS: $0
- Payout Ratio: 0.0%
Important Dates
- Next Earnings Date: 2021-11-04
- Next Ex-Dividend Date:
Price Trends
- Current Stock Price: $605.18
- 52-week high: $686.62
- 52-week low: $441
- 200-day moving average: $555.64
- 50-day moving average: $650.38
Performance
- 1-Month Price Return: -8.5%
- 3-Month Price Return: 11.1%
- 6-Month Price Return: 26.0%
- 1-Year Price Return: 5.8%
- 2-Year Price Return: 121.9%
- 5-Year Price Return: 49.3%
Visit the Passiv Stock Directory
Data provided by IEX Cloud
For Canadian securities, listen to free conference calls on the TSX Quarterly Podcast